DAPA-CKD Data Put AstraZeneca’s Farxiga Out Front
A 39% relative risk reduction in the primary endpoint for the DAPA-CKD study and a 31% reduction in all-cause mortality prime Farxiga for a new chronic kidney disease indication following filings due in the next few months.
You may also be interested in...
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of developments in the global biopharmaceutical industry.
Boehringer Ingelheim and Eli Lilly’s SGLT2 inhibitor Jardiance (empagliflozin) reduces cardiovascular deaths and hospitalizations in certain heart failure patients regardless of whether they have diabetes, and regulatory submissions are expected for the additional indication later this year.
Study assessed Farxiga’s effect on renal outcomes and CV mortality in chronic kidney disease patients with and without type 2 diabetes.